Literature DB >> 28667367

Platelets, circulating tumor cells, and the circulome.

Preeti Kanikarla-Marie1, Michael Lam1, David G Menter1, Scott Kopetz2.   

Abstract

Platelets are cytoplasmic fragments generated by megakaryocytes in the bone marrow and do not possess a nucleus. They contribute to the "Circulome" consisting of all circulating cells, factors and macromolecules such as cfDNA. Their primary function is to recognize vascular lesions and initiate thrombus formation that ceases bleeding. This distinctive characteristic of platelets also contributes to cancer and its progression. The ability of platelets to recognize and interact with other cells and neighboring platelets enables them to interact with tumor cells in the circulation. Receptor recognition and factor mediated crosstalk between tumor cells and platelets stimulate platelet activation, release of factors, and aggregation that promotes tumor cell survival and cancer progression. This review describes platelet: (i) contributions to the "Circulome" (ii) their importance as diagnostic tools in predicting cancer risk and (iii) therapies targeting platelet activation in inhibiting tumor progression and metastasis.

Entities:  

Keywords:  CTC; Circulating tumor cells; Circulome; Colorectal cancer; Liquid biopsy; Tumor-educated platelets; cfDNA

Mesh:

Substances:

Year:  2017        PMID: 28667367     DOI: 10.1007/s10555-017-9681-1

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  24 in total

1.  Drug Targeting via Platelet Membrane-Coated Nanoparticles.

Authors:  Shuyan Wang; Yaou Duan; Qiangzhe Zhang; Anvita Komarla; Hua Gong; Weiwei Gao; Liangfang Zhang
Journal:  Small Struct       Date:  2020-09-09

2.  RNA Sequencing of Tumor-Educated Platelets Reveals a Three-Gene Diagnostic Signature in Esophageal Squamous Cell Carcinoma.

Authors:  Tiejun Liu; Xin Wang; Wei Guo; Fei Shao; Zitong Li; Yang Zhou; Zhihong Zhao; Liyan Xue; Xiaoli Feng; Yin Li; Fengwei Tan; Kai Zhang; Qi Xue; Shugeng Gao; Yibo Gao; Jie He
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

Review 3.  Nanotechnology in Radiation Oncology.

Authors:  Bo Sun; C Tilden Hagan; Joseph Caster; Andrew Z Wang
Journal:  Hematol Oncol Clin North Am       Date:  2019-10-01       Impact factor: 3.722

Review 4.  Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Authors:  Preeti Kanikarla-Marie; Michael Lam; Alexey V Sorokin; Michael J Overman; Scott Kopetz; David G Menter
Journal:  Front Oncol       Date:  2018-04-20       Impact factor: 6.244

5.  LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis.

Authors:  Chang-Liang Luo; Zhi-Gao Xu; Hao Chen; Jia Ji; Yu-Hui Wang; Wei Hu; Kun Wang; Wu-Wen Zhang; Chun-Hui Yuan; Fu-Bing Wang
Journal:  Cancer Manag Res       Date:  2018-06-08       Impact factor: 3.989

Review 6.  Deciphering Platelet Kinetics in Diagnostic and Prognostic Evaluation of Hepatocellular Carcinoma.

Authors:  Bibek Aryal; Munekazu Yamakuchi; Toshiaki Shimizu; Jun Kadono; Akira Furoi; Kentaro Gejima; Teruo Komokata; Teruto Hashiguchi; Yutaka Imoto
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-27

7.  Platelet count, aspirin use, and characteristics of host inflammatory responses in colorectal cancer.

Authors:  Juha P Väyrynen; Sara A Väyrynen; Päivi Sirniö; Ilkka Minkkinen; Kai Klintrup; Toni Karhu; Jyrki Mäkelä; Karl-Heinz Herzig; Tuomo J Karttunen; Anne Tuomisto; Markus J Mäkinen
Journal:  J Transl Med       Date:  2019-06-13       Impact factor: 5.531

Review 8.  Platelets and Hepatocellular Cancer: Bridging the Bench to the Clinics.

Authors:  Quirino Lai; Alessandro Vitale; Tommaso M Manzia; Francesco G Foschi; Giovanni B Levi Sandri; Martina Gambato; Fabio Melandro; Francesco P Russo; Luca Miele; Luca Viganò; Patrizia Burra; Edoardo G Giannini
Journal:  Cancers (Basel)       Date:  2019-10-15       Impact factor: 6.639

9.  Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients.

Authors:  Weelic Chong; Zhenchao Zhang; Rui Luo; Jian Gu; Jianqing Lin; Qiang Wei; Bingshan Li; Ronald Myers; Grace Lu-Yao; William Kevin Kelly; Chun Wang; Hushan Yang
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.638

10.  Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer.

Authors:  Qianqian Ren; Peng Zhu; Hui Zhang; Tianhe Ye; Dehan Liu; Zhao Gong; Xiangwen Xia
Journal:  Cancer Cell Int       Date:  2020-03-24       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.